Shorter trastuzumab treatment for HER2+ breast cancer can be as effective, with fewer cardiac side-effects - Medical Xpress

Medical Xpress

Shorter trastuzumab treatment for HER2+ breast cancer can be as effective, with fewer cardiac side-effects Medical Xpress A phase III randomized clinical trial of 4,088 women with HER2-positive, early-stage breast cancer found that taking trastuzumab (Herceptin) for 6 months was non-inferior to the current standard of 12 months. The disease-free survival rate at four ... Test of Herceptin Finds Briefer Treatment Can Work, With Fewer Side EffectsWBUR Short'n'SweetGenomeWeb Good News on Early Breast Cancer: Herceptin Treatment Can Be ShortenedNew York Times HealthNewsReview.org -Bloomberg -New Jersey Herald -Oncology Nurse Advisor all 58 news articles »

from Health - Google News https://ift.tt/2KANLWt